Tenderwize
Back to tender search

Non-exclusive discount agreement for Nadroparin

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Oct 27, 2026 · 65 days left·Open·Supplies·Framework
Original notice title

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Nadroparin (ATC-Code: B01AB06).

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

40 / 100

Complexity

20 / 100

Risk factors

Open-house contracts terminate automatically when exclusive discount contracts take effect, which may happen 6-8 months...

Since the agreement is non-exclusive and open to all, there is no minimum purchase commitment from the buyer.

No procurement documents available

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Supply of Nadroparin (ATC B01AB06) under a non-exclusive discount agreement
  • Open-house model with uniform conditions for all participants
Show full summary

This is a non-exclusive discount agreement (open-house model) for pharmaceutical products containing Nadroparin (ATC B01AB06) offered by AOK Niedersachsen. It is a bridge between patent expiry and exclusive contracts. Any pharmaceutical entrepreneur meeting eligibility can join at any time from 2025-01-01 to 2026-12-31. The first entry deadline is 2024-11-27. The contract is not a public procurement; it uses a transparency publication.

Risks

Open-house contracts terminate automatically when exclusive discount contracts take effect, which may happen 6-8 months...

Since the agreement is non-exclusive and open to all, there is no minimum purchase commitment from the buyer.

No procurement documents available

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG
  • Must have seat in EU/EEA or Germany
  • Only the active ingredient Nadroparin (ATC B01AB06) is covered

Award Criteria

Lot 1

Price - no further details

Buyer

Location

Hannover, DEU

Identifier

AOK- Niedersachsen. Die Gesundheitskasse

Activity

Health

Lots (1)

LOT-0000

Non-exclusive discount agreement for Nadroparin

Open-house model for Nadroparin (ATC B01AB06) from 2025-01-01 to 2026-12-31. All pharmaceutical companies may join under uniform conditions. Contracts end automatically when exclusive contracts come into effect. The first sign-up deadline is 2024-11-27; later entry possible monthly with 35-day advance notice.

SuppliesFrameworkEU fundedElectronic submission

Location

DE929, Germany

Duration

Dec 2024 - Dec 2026

Category

Pharmaceutical products

Award Criteria

Price

Deadline

Expired Nov 27, 2024

Procurement Details

Publication date
04 Nov 2024
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
671589-2024

Similar tenders